- Home
- NCPL vs TCRT Comparison
NCPL vs TCRT Comparison
Compare NCPL & TCRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCPL
- TCRT
- Stock Information
- Founded
- NCPL 1984
- TCRT 1998
- Country
- NCPL United States
- TCRT United States
- Employees
- NCPL N/A
- TCRT N/A
- Industry
- NCPL Investment Managers
- TCRT Biotechnology: Pharmaceutical Preparations
- Sector
- NCPL Finance
- TCRT Health Care
- Exchange
- NCPL Nasdaq
- TCRT Nasdaq
- Market Cap
- NCPL 4.3M
- TCRT 3.8M
- IPO Year
- NCPL N/A
- TCRT N/A
- Fundamental
- Price
- NCPL $1.92
- TCRT $2.85
- Analyst Decision
- NCPL
- TCRT
- Analyst Count
- NCPL 0
- TCRT 0
- Target Price
- NCPL N/A
- TCRT N/A
- AVG Volume (30 Days)
- NCPL 42.6K
- TCRT 40.1K
- Earning Date
- NCPL 03-17-2025
- TCRT 05-19-2025
- Dividend Yield
- NCPL N/A
- TCRT N/A
- EPS Growth
- NCPL N/A
- TCRT N/A
- EPS
- NCPL N/A
- TCRT N/A
- Revenue
- NCPL $812,612.00
- TCRT $10,000.00
- Revenue This Year
- NCPL N/A
- TCRT $5,680,500.00
- Revenue Next Year
- NCPL $101.16
- TCRT N/A
- P/E Ratio
- NCPL N/A
- TCRT N/A
- Revenue Growth
- NCPL N/A
- TCRT 100.00
- 52 Week Low
- NCPL $1.41
- TCRT $1.31
- 52 Week High
- NCPL $22.82
- TCRT $14.20
- Technical
- Relative Strength Index (RSI)
- NCPL 50.02
- TCRT 56.46
- Support Level
- NCPL $1.75
- TCRT $2.56
- Resistance Level
- NCPL $2.15
- TCRT $2.91
- Average True Range (ATR)
- NCPL 0.10
- TCRT 0.28
- MACD
- NCPL -0.01
- TCRT 0.02
- Stochastic Oscillator
- NCPL 42.50
- TCRT 79.81
About NCPL Netcapital Inc.
Netcapital Inc is a financial technology company. The company facilitates the growth of private companies by providing fundraising services and other consulting services. The company's online private investment platform connects entrepreneurs and investors, enabling companies to raise capital digitally. The Company operates in a single operating segment, which is the provision of fintech services.
About TCRT Alaunos Therapeutics Inc.
Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations. It has a single reportable and operating segment related to biopharmaceutical research and development.